BTK Inhibitors in “Other” B-Cell Malignancies

Download these slides from our ASH 2019 live satellite symposium on safety and optimal use of BTK inhibitors to review the most current clinical data on treating patients with diverse hematologic malignancies.
John Pagel Headshot
John Pagel, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 421 KB
Released: December 6, 2019


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by educational grants from
BeiGene, Ltd.
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company

Related Content

ASCO 2020 data on treatment with nivolumab plus brentuximab vedotin in standard-risk young patients with R/R classical Hodgkin lymphoma as reported by Clinical Care Options (CCO)

Released: June 3, 2020

From ASCO 2020, new data confirm significant efficacy and tolerability of acalabrutinib in CLL and other B-cell malignancies, reported by Clinical Care Options (CCO)

Released: June 3, 2020

Latest data from a phase I study of AMG 330 in patients with acute myeloid leukemia from ASCO 2020, as reported by Clinical Care Options (CCO)

Released: June 2, 2020

Updated data from phase III BELLINI study of venetoclax plus bortezomib/dexamethasone in R/R myeloma from ASCO 2020 as reported by Clinical Care Options (CCO)

Released: June 2, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?